Kornimate/medical-research-clean huggingface dataset:
adipose-derived svf for treatment of alopecia

Conditions: Androgenetic Alopecia

Summary: the general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived svf for the treatment of alopecia.


Eligibility criteria:
inclusion criteria: 1. males and females 18 - 60 years of age and older that have been diagnosed with androgenetic alopecia. 2. subjects will be in good health (asa class i-ii) with a bmi \< 35. must have at least a 2cm x 2cm spot on the scalp which shows evidence of alopecia without scarring or traumatic injury 3. able and willing to make the required study visits. 4. able and willing to give consent and follow study instructions. 5. must speak, read and understand english exclusion criteria: 1. history of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days prior to injection 2. allergic to lidocaine, epinephrine, valium or sodium phosphate 3. individuals with a propensity for keloids 4. individuals with diminished decision-making capacity will not be included in this research study 5. current use of anti-inflammatory or anticoagulation medications that affect bleeding or are for bleeding disorders. these include: plavix, warfarin (coumadin, jantoven, marfarin). in addition, if any of the following medicines are used two (2) weeks prior to surgery the patient will be ineligible. 6. use of concomitant treatments, including topical medications, oral medications, meso-therapy, non-ablative fractional laser treatment, low-level laser therapy, interfollicular prp injection and hair transplantation within the preceding 6 months. 7. all smokers and other tobacco users.
optimization study of the wraparound care for youth injured by violence program

Conditions: Violence; Violence, Non-accidental; Physical Violence

Summary: this study is an optimization study to evaluate how a wraparound program for youth who have been injured by violence helps to change violence related attitudes and beliefs, change individual risk factors for violence and reduce the risk of future injury due to violence. wraparound care involves linking the youth with a support worker who will work with the youth to develop positive support networks and help them link with services that address risk factors towards future violence.

in canada, violence is the most common reason for youth (aged 12- 24) to visit an emergency department (ed) and the leading cause of hospitalization among males aged 20 to 24. injury is a chronic, recurring disease. in winnipeg, canada, 20% of youth injured by violence visited the same ed in the next year with a repeat injury due to violence. currently the standard of care for this vulnerable population is to discharge them from our eds with no effort to prevent the next injury. there are 5 components key to implementing wraparound care for youth who are at risk of violence. the 1st component is the establishment of a relationship between support worker and youth at the time of injury - i.e. during a teachable moment. the 2nd component is that the support worker has extensive "lived experience". many youth affected by violence have been marginalized by society and have significant trust issues with figures of traditional power (i.e. doctors, social workers etc.). it is imperative that the support worker establish trust quickly and act as a role model. the 3rd component is that the care program is individualized for and by each youth. the support worker helps the youth to define their own goals and the steps required to achieve them. the 4th component is to provide trauma-informed care. trauma-informed care is an approach used by caregivers that acknowledges the current and past traumas a person may have experienced and helps the person heal and build a sense of control over their lives. the final component is the opportunity to access community supports within their own culture.

Eligibility criteria:
inclusion criteria: 1) age 14 - 24, and 2) presentation with an injury due to violence (defined as an injury inflicted by someone else and one caused by a gunshot wound, stab wound, blunt object, or bodily force). exclusion criteria: 1) unable to consent due to language or brain injury, 2) sexual assault, 3) child abuse, 4) self-inflicted injury, or 5) transfer from hospital \> 1 hr from winnipeg, canada

Keywords: youth violence, intervention, emergency medicine
risk of cardiovascular events in patients with type 2 diabetes initiating oral antidiabetic treatments

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare the incidence of major cardiovascular events among patients with type 2 diabetes who are new initiators of saxagliptin and those who are new initiators of oral anti-diabetic drugs (oads)in classes other than dipeptidyl peptidase iv (dpp4) inhibitors.

prospectively designed retrospective database study. this study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice

Eligibility criteria:
inclusion criteria: * 18 years of age or older * newly prescribed saxagliptin or an oad in a class other than dpp4 inhibitors * enrolled in the respective database for at least 180 days prior to the first prescription for saxagliptin or other oad in a class other than dpp4 inhibitors exclusion criteria: * patients identified with a diagnostic code for any of the cardiovascular outcomes of interest within the 180-day baseline period * patients prescribed a dpp4 inhibitor during the baseline period
the effect of preoperative inflammation-based scores on postoperative morbidity and mortality for laparoscopic gastrectomy

Conditions: Stomach Neoplasms

Summary: the purpose of this study is to explore the effect of preoperative inflammation-based scores on postoperative morbidity and mortality for laparoscopic gastrectomy.

a prospective cohort study will be performed to explore the effect of preoperative inflammation-based scores on postoperative morbidity and mortality for laparoscopic gastrectomy.the evaluation parameters are perioperative clinical efficacy, postoperative complications and 3-year survival and recurrence rates.

Eligibility criteria:
inclusion criteria:age from 18 to 75 years * primary lower third gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy * ct2-4a, n0-3, m0 at preoperative evaluation according to the american joint committee on cancer (ajcc) cancer staging manual seventh edition * no distant metastasis is observed. and the spleen, pancreas or other adjacent organs are not involved by the tumor. * performance status of 0 or 1 on eastern cooperative oncology group scale (ecog) * american society of anesthesiology score (asa) class i, ii, or iii * written informed consent exclusion criteria:• women during pregnancy or breast-feeding * severe mental disorder * history of previous upper abdominal surgery (except laparoscopic cholecystectomy) * history of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection * enlarged or bulky regional lymph node envelop important vessels * history of other malignant disease within past five years * history of previous neoadjuvant chemotherapy or radiotherapy * history of unstable angina or myocardial infarction within past six months * history of cerebrovascular accident within past six months * history of continuous systematic administration of corticosteroids within one month * requirement of simultaneous surgery for other disease * emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * fev1\<50% of predicted values
effect of perioperative hypothermia on postoperative pain

Conditions: Postoperative Pain

Summary: this study aims to observe the impact of perioperative body temperature on postoperative pain and pain sensitization for the patients with laparoscopic surgery. based on this study the investigators aimed to explore the effect of perioperative hypothermia on postoperative pain.

this study aims to included surgery patients to observe the impact of perioperative body temperature on postoperative pain and pain sensitization for the patients with laparoscopic surgery. body temperature and postoperative pain will be continuously assessed, and then association analysis will be performed.

Eligibility criteria:
inclusion criteria: * age 18-70 years old * american society of anesthesiologists i-iii * patients who plan to laparoscopic surgery under general anesthesia * volunteer to participate in this study and sign informed consent. exclusion criteria: * the patient with chronic pain * patients with fever * the patient is infected * severe vision, hearing, language impairment or other reasons unable to communicate with visitors * patients with known mental illness or lack of communication or cognitive impairment before operation; * long-term use of sedatives, antidepressants or alcoholism * artificial cooling and low temperature protection were taken during the operation
duke autoimmunity in pregnancy registry

Conditions: Pregnancy; Systemic Lupus Erythematosus; Cutaneous Lupus; Rheumatoid Arthritis; Sjogren's Syndrome; Scleroderma

Summary: it is difficult to predict how a women with an autoimmune disease will do during pregnancy. some women will improve, others will worsen. some pregnancies progress normally and others become very complicated. the duke autoimmunity in pregnancy (dap) registry will enroll women with autoimmune diseases, such as lupus, rheumatoid arthritis, scleroderma, and sjogren's syndrome who wish to become, or already are, pregnant. we will follow these women throughout pregnancy to better understand how their autoimmune disease affects their pregnancy, and vice versa.

women with a systemic autoimmune disease that would be followed by a rheumatologist will be included in this study. all women will be seen every 4-6 weeks throughout pregnancy. at each visit, women will complete a questionnaire, the physician will determine the current level of disease activity, and a blood sample will be taken. for women with lupus and healthy women, and additional visit will occur at the start of the 3rd trimester for a closer evaluation of predictors of preterm birth. this is not an intervention study. women will not be given experimental medication. all recommendations for treatment and monitoring will be made based on the best available data with input from the treating obstetrician. women in this registry are not required to be seen by duke obstetrics nor to deliver at a duke hospital.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * desire for pregnancy within 6 months or currently pregnant * women with systemic autoimmune disease, including: * lupus (systemic lupus erythematosus or cutaneous lupus) * antiphospholipid syndrome or positive antiphospholipid antibodies * rheumatoid arthritis * scleroderma (systemic sclerosis) * sjogren's syndrome * inflammatory arthritis (including psoriatic arthritis and ankylosing spondylitis) * undifferentiated connective tissue disease (uctd) * vasculitis * myositis (polymyositis or dermatomyositis) * positive ro/ssa or la/ssb antibodies exclusion criteria: * unable to speak english * unable to provide informed consent * unable to travel to duke university for follow-up visits

Keywords: pregnancy lupus (systemic lupus erythematosus or cutaneous lupus) rheumatoid arthritis sjogren's syndrome scleroderma
emr versus esd for barrett's neoplasia

Conditions: Barretts Esophagus With Dysplasia; Barrett Adenocarcinoma; Esophageal Cancer

Summary: rationale: the optimal technique for removal of visible dysplastic lesions in barrett's esophagus remains controversial. endoscopic mucosal resection (emr) is safe, effective, easy to apply, and has been the most widely used technique since 2008. endoscopic submucosal dissection (esd) is a more controlled dissection method with potential improved efficacy, but at the cost of higher technical complexity. objective: the investigators aim to compare emr and esd for removal of visible lesions in barrett's esophagus. study design: randomized clinical trial study population: patients with barrett's esophagus and a visible lesion with dysplasia and/or early cancer. suspicion for submucosal invasion is an exclusion criterion. intervention: patients are randomized to receive either emr or esd, with follow-up and no ablation during 12 months after the resection. main study endpoint: primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.


Eligibility criteria:
inclusion criteria: * patients age: ≥ 18 years * willingness to undergo both emr or esd * ability to provide written, informed consent (approved by irb) and understand the responsibilities of trial participation * be with a single visible lesion with absence of signs of submucosal invasion on endoscopy, after evaluation by the adjudication committee. exclusion criteria: * patients with visible lesions with suspicion of submucosal invasion bases on assessment of the adjudication committee * history of esophageal surgery other than fundoplication * history of esophageal ablation therapy or endoscopic resection * multiple visible lesions in the be segment at baseline * uncontrolled coagulopathy with inr \>2.0, thrombocytopenia with platelet counts \< 50,000 * subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment in-structions, or follow-up guidelines * life expectancy \<2 years

Keywords: barrett's esophagus esophagheal adenocarcinom
nutritional rehabilitation and sleep apnea in the obese

Conditions: Obese; Sleep Apnea, Obstructive

Summary: in obese patients, the prevalence of obstructive sleep apnea (osa) is around 40% in men and 30% in women. weight loss after bariatric surgery significantly improves osa, with 75% of patients having a reduction in osa severity or becoming non-apneic. we hypothesize a similar effect on osa of nutritional and psychocomportemental rehabilitation for obese patients. however, we expect weight loss and blood pressure reduction to probably be lower in obese patients who have osa and nutritional rehabilitation alone than in those who are treated for their osa or are without osa. to address this question, we will conduct an observational study on obese patients, treated or not for osa, following nutritional and psychocomportemental rehabilitation.

in obese patients, osa prevalence is around 40% in men and 30% in women. being overweight or obese are independent risk factors for osa, and the prevalence increases with body mass index (bmi). weight loss after bariatric surgery is one treatment for osa, 75% of patients having a reduction in osa severity or becoming non-apneic. osa and obesity both induce type 2 diabetes, hypertension and/or nonalcoholic fatty liver disease (nafld). a randomized study (chirinos et al. nejm 2014) demonstrated a better improvement in blood pressure, triglyceride levels or insulin resistance with weight loss alone or weight loss associated with continuous positive airway pressure (cpap) than with cpap alone. we hypothesize a similar effect of nutritional and psychocomportemental rehabilitation on osa. however, weight loss and blood pressure improvements could be lesser in untreated osa patients than in treated osa or non-osa patients. it has been demonstrated that bariatric surgery reduces medication use such as antihypertensive or antidiabetic drugs, and thus a secondary objective is to determine whether nutritional and psychocomportemental rehabilitation similarly reduces medication use by the overweight and obese.

Eligibility criteria:
inclusion criteria: * bmi \> 25 kg/m² and/or waist circumference \> 80 cm in women or 94 cm in men * patients registered to follow a nutritional psychocomportemental reeducation program with the "ethique et santé" group exclusion criteria: - subjects covered by articles l1121-5 to l1121-8 of french law

Keywords: obesity sleep apnea hypertension type 2 diabetes cpap
the effect of alfacalcidol on muscle strength in elderly indonesian women : a randomized controlled trial

Conditions: Muscle Weakness

Summary: the age-related increase in falls is strongly associated with a decline in muscle strength by the mechanism of sarcopenia. there has been great interest in developing approaches to counteract the effects of sarcopenia, and thereby reduce the age-related decline in muscle mass with vitamin d that have muscular effect. however, a limited number of studies demonstrate a vitamin d analog (alfacalcidol) increase in lower body muscle strength in adults with vitamin d deficiency. a double-blinded randomized controlled trial was conducted in order to determine the effect of alfacalcidol on the upper-body muscle strength in indonesian elderly women in age group of 60 or more who had low handgrip strength.

a total 122 elderly women were enrolled to this study. it was determined subjects with handgrip strength less than 22 kg and measured using handheld dynamometer. there were 95 subjects fulfilled the eligible criteria. these subjects were randomized into two groups, one group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo. each subject was given calcium 500 mg/day. after 12 weeks of intervention, 88 subjects had the second muscle strength measurement (7 dropped out).

Eligibility criteria:
inclusion criteria: * elderly women in age group of 60 or more * subjects with handgrip strength less than or equal to 22 kg exclusion criteria: * hypercalcemia (serum calcium \> 10.5 mg / dl) * can not understand instructions well (mmse scale \< 16) * depression (geriatric depression scale\> 10) * fracture, deformity, and pain with a visual analog scale (vas) ≥ 4 on fingers and joints of the upper limb when the examination will be conducted * heart failure fc. iii-iv or uncontrolled according to the new york heart association (nyha) * neurological conditions (epilepsy, acute stroke, parkinson's) * malignant hypertension (systolic blood pressure ≥ 200 mmhg and or diastolic blood pressure ≥ 120 mmhg) * blood malignancies and solid tumors * decreased function of the liver (cirrhosis, alt increase above 2 times the upper normal limit ) * refusing to follow the research / not willing controls

Keywords: alfacalcidol falls handgrip muscle strength sarcopenia
a prospective study to examine the need to adjust the dose of apixaban when used in atrial fibrillation and obesity

Conditions: Anticoagulant; Apixaban; Obesity

Summary: a prospective cohort study to determine whether a high body weight (bmi equal to or greater than 35 kg / m 2) has an effect on anticoagulant apixaban level in the blood of patients with atrial fibrillation.


Eligibility criteria:
inclusion criteria: - hospitalized patients on steady state level of apixaban, based on the data given in the hospital ward . a level of steady state is received within two days of treatment. exclusion criteria: * anasarca * acute renal failure
a trial of an investigational drug for the prevention of diarrhea associated with irinotecan/5fu/leucovorin chemotherapy in previously untreated metastatic colorectal cancer

Conditions: Colorectal Neoplasms; Diarrhea

Summary: the study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer. the standard and approved treatment for colorectal cancer is to undergo chemotherapy with a combination of irinotecan (also known as cpt-11, camptosar), 5-fluorouracil (also known as 5-fu), and leucovorin (also known as lv). this is known as the triple therapy. one of the major side effects of cpt-11/5-fu/lv chemotherapy treatment is diarrhea. the purpose of this research study is to see whether adding this investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. this study will also determine if adding the investigational drug to triple therapy has a positive effect on tumors.


Eligibility criteria:
other specific inclusion/exclusion criteria may apply. in order to determine eligibility, further examination by the investigator is necessary. inclusion criteria: * age 18 years or older * diagnosis of colorectal cancer or adenocarcinoma of the appendix * a tumor mass that can be measured * resolution of all toxic effects of any radiotherapy or surgical procedures to nci ctc grade less than or equal to 1 * willingness and ability to comply with scheduled visits, treatment plan, and laboratory tests, and other study procedures exclusion criteria: * women that are pregnant or lactating * prior treatment with irinotecan * partial or complete bowel obstruction, known chronic malabsorption, or total colectomy or other major abdominal surgery that might result in substantial alteration in transit or absorption of oral medication * administration of the last dose of any previous adjuvant therapy for colorectal cancer within 6 months previous to randomization * current enrollment in another clinical trial * administration of any prior systemic anticancer therapy for metastatic colorectal cancer

Keywords: pharmacia